FDA approval of Indivior PLC's Sublocade (buprenorphine extended-release) gives healthcare professionals another weapon to fight the growing opioid addiction epidemic in the US. It also gives the UK-based company another product in the battle to maintain its dominant share of the opioid use disorder (OUD) market.
Indivior has seen the market share for its blockbuster OUD treatment Suboxone (buprenorphine/naloxone) sublingual film dip slightly as price-sensitive payers...







